<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810108</url>
  </required_header>
  <id_info>
    <org_study_id>10894</org_study_id>
    <nct_id>NCT00810108</nct_id>
  </id_info>
  <brief_title>Lopinavir/Ritonavir (Kaletra) PK in Children</brief_title>
  <official_title>Pharmacokinetics of Lopinavir Crushed Versus Whole Tablets in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Association of Colleges of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the pharmacokinetics of lopinavir tablets
      administered to pediatric patients as either whole or crushed tablets. The study is a
      randomized,open-label, crossover study of pediatric subjects already taking
      lopinavir/ritonavir tablets as part of their clinical care. THe investigators hypothesize
      that lopinavir exposure in pediatric patients will be lower after taking a dose of the tablet
      formulation, crushed and mixed with pudding or yogurt, as compared to the exposure after
      taking a dose with tablets swallowed whole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By the end of 2005, approximately 2.3 million children worldwide were living with HIV/AIDS.1
      At least 660,000 children worldwide have advanced HIV/AIDS and are in dire need of
      antiretroviral treatment. While many barriers exist to scaling up HIV/AIDS care and treatment
      globally, access to life-saving treatments for children is increasing. The protease
      inhibitor, lopinavir/ritonavir (Kaletra®), is recommended as a first-line agent by the World
      Health Organization and by the US Department of Health and Human Services for the treatment
      of pediatric patients in resource-limited settings and in the United States.

      The prescribing information states that these tablets may not be crushed, broken or chewed,
      and the manufacturer does not plan to examine the pharmacokinetics of crushed tablets at this
      time. The company found that the crushed tablets were poorly absorbed in a small
      pharmacokinetic study in several dogs. While this information has spread through
      investigators by word-of-mouth, this information has not been published in any forum by the
      company, and no guidance as to the extent of the decrease in absorption has been provided.
      However, patients and caregivers are dosing pediatric patients with crushed tablets to
      overcome some of the limitations of the oral solution. If crushed tablet administration
      yields significantly lower systemic exposure to lopinavir than whole tablets, then patients
      using this administration technique will be at higher risk for development of viral
      resistance and treatment failure. This administration technique must be studied so that
      providers have evidence to support recommendations about this dose administration strategy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lopinavir Area Under the Curve (AUC)</measure>
    <time_frame>pre-dose, 1,2,4,6,8, and 12 hours post-dose</time_frame>
    <description>Lopinavir Area Under the Plasma Concentration versus Time Curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>HIV/AIDS Treatment</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Whole Then Crushed Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects will take whole lopinavir tablets at Study Visit 1, and crushed tablets at Study Visit 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crushed Then Whole Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects will take crushed tablets at Study Visit 1, and whole tablets at Study Visit 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir (Kaletra®) tablets</intervention_name>
    <description>The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).</description>
    <arm_group_label>Whole Then Crushed Tablets</arm_group_label>
    <arm_group_label>Crushed Then Whole Tablets</arm_group_label>
    <other_name>Kaletra®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV infection

          -  Taking lopinavir/ritonavir (Kaletra) tablets at standard pediatric doses for greater
             than two weeks

          -  Concomitant medications and/or natural products, including potentially interacting
             products, have been stable for greater than two weeks and are not expected to change
             over the course of the study

          -  Ability to understand study procedures and assent to participate

          -  Parental or guardian consent

          -  Aged 6 - 17 years

        Exclusion Criteria:

          -  Acute serious medical illness or infection (in the judgment of the
             investigator)requiring treatment and/or hospitalization within 14 days prior to study
             entry

          -  Pregnancy

          -  Concomitant medications/natural products that have been started within past two weeks
             and/or that will be changed over the course of the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brookie Best, PharmD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego - Skaggs School of Pharmacy and School of Medicine</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <results_first_submitted>April 25, 2012</results_first_submitted>
  <results_first_submitted_qc>June 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 6, 2012</results_first_posted>
  <last_update_submitted>June 2, 2012</last_update_submitted>
  <last_update_submitted_qc>June 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</investigator_affiliation>
    <investigator_full_name>Brookie Best</investigator_full_name>
    <investigator_title>PharmD, MAS</investigator_title>
  </responsible_party>
  <keyword>HIV/AIDS</keyword>
  <keyword>pediatrics</keyword>
  <keyword>resource-limited settings</keyword>
  <keyword>lopinavir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>Kaletra®</keyword>
  <keyword>antiretroviral treatment</keyword>
  <keyword>crushed tablets</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited between August 2008 to August 2009 from the Special Immunology Program at Children' National Medical Center in Washington DC.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Whole Then Crushed Tablets</title>
          <description>These subjects will take whole lopinavir tablets at Study Visit 1, and crushed tablets at Study Visit 2.</description>
        </group>
        <group group_id="P2">
          <title>Crushed Then Whole Tablets</title>
          <description>These subjects will take crushed tablets at Study Visit 1, and whole tablets at Study Visit 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Whole Then Crushed Tablets</title>
          <description>These subjects will take whole lopinavir tablets at Study Visit 1, and crushed tablets at Study Visit 2.</description>
        </group>
        <group group_id="B2">
          <title>Crushed Then Whole Tablets</title>
          <description>These subjects will take crushed tablets at Study Visit 1, and whole tablets at Study Visit 2.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" lower_limit="10" upper_limit="16"/>
                    <measurement group_id="B2" value="13" lower_limit="12" upper_limit="16"/>
                    <measurement group_id="B3" value="13" lower_limit="10" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lopinavir Area Under the Curve (AUC)</title>
        <description>Lopinavir Area Under the Plasma Concentration versus Time Curve (AUC)</description>
        <time_frame>pre-dose, 1,2,4,6,8, and 12 hours post-dose</time_frame>
        <population>All subjects who completed the pharmacokinetic sampling visits with whole tablet administration were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects Taking Whole Tablets</title>
            <description>Lopinavir AUC from all subjects taking the whole tablet</description>
          </group>
          <group group_id="O2">
            <title>All Subjects Taking Crushed Tablets</title>
            <description>Lopinavir AUC from all subjects taking the crushed tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Lopinavir Area Under the Curve (AUC)</title>
          <description>Lopinavir Area Under the Plasma Concentration versus Time Curve (AUC)</description>
          <population>All subjects who completed the pharmacokinetic sampling visits with whole tablet administration were analyzed</population>
          <units>mg*hr/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="101" upper_limit="202"/>
                    <measurement group_id="O2" value="92" lower_limit="79" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lopinavir AUC was compared between whole tablet and crushed tablet administration by using a ratio of crushed/whole AUC.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The geometric mean and 90% confidence interval assessed whether the crushed and whole tablet administration AUCs were equivalent.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Ratio of Crushed/Whole Tablet AUC</param_type>
            <param_value>0.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>Data from all subjects combined</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The AUC of the crushed tablet administration were measured after a single dose only, rather than at steady-state; variable adherence may have impacted results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brookie M. Best, Associate Professor</name_or_title>
      <organization>University of California San Diego</organization>
      <phone>858-822-5550</phone>
      <email>brookie@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

